## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Investment Management Corp of Ontario Trims Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251209T150817 | Somewhat-Bullish | Relevance: 99%
-  Investment Management Corp of Ontario (IMCO) reduced its stake in Gilead Sciences (NASDAQ:GILD) by 11.1% in Q2 2025, selling 22,806 shares and ending with 181,827 shares valued at $20.159 million. Despite this, institutional ownership of Gilead remains high at 83.67%, with other major firms like Norges Bank, Price T Rowe, Invesco, and Vanguard increasing their positions. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $130.65, with some recent price target increases into the $135â€“$145 range.

**2. CIBC Asset Management Inc Sells 28,874 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251211T101122 | Somewhat-Bullish | Relevance: 99%
-  CIBC Asset Management Inc has reduced its stake in Gilead Sciences, Inc. by 6.6%, selling 28,874 shares and now holding 408,963 shares valued at approximately $45.34 million. Gilead Sciences reported strong quarterly earnings, beating estimates with $2.47 EPS on $7.77 billion in revenue, and set a positive FY2025 guidance. The company also declared a quarterly dividend of $0.79, while analysts maintain a "Moderate Buy" rating with an average price target of $130.96.

**3. Why You Might Be Interested In Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming Dividend**
- Source: Simply Wall Street | 20251210T120821 | Bullish | Relevance: 99%
-  Gilead Sciences, Inc. (NASDAQ:GILD) is expected to trade ex-dividend soon, offering a dividend payment of US$0.79 per share, totaling US$3.16 annually, which translates to a 2.6% trailing yield. The company's dividend appears sustainable, with payout ratios of 48% of profit and 43% of free cash flow, and it has maintained steady earnings per share growth of 9.0% over the last five years, contributing to a 6.3% average annual dividend increase. These factors suggest Gilead Sciences warrants closer examination for dividend investors.

**4. Gilead Sciences stock reaches all-time high at 124.63 USD**
- Source: Investing.com | 20251211T111800 | Bullish | Relevance: 99%
- Gilead Sciences Inc. stock reached an all-time high of $124.63 USD, marking a significant 34.5% increase over the past year and outperforming many biotechnology peers. The company reported strong third-quarter 2025 earnings, exceeding analyst expectations, despite a setback with its cancer drug Trodelvy in a Phase 3 trial. Gilead continues to demonstrate strong market positioning, robust pipeline development, and a consistent dividend record.

**5. Dymon Asia Capital Singapore PTE. LTD. Purchases Shares of 18,000 Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251210T110803 | Bullish | Relevance: 99%
- Dymon Asia Capital Singapore PTE. LTD. recently acquired 18,000 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $1.996 million, making it their 17th largest holding. Gilead reported strong Q3 earnings, beating EPS and revenue estimates, and announced a quarterly dividend of $0.79 per share. Analysts generally rate Gilead as a "Moderate Buy" with a consensus target price of $130.65, despite recent insider share sales totaling over $16 million.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 14.1x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $152.9B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 14.1 |
| Current P/E | 15.1 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.6% to -0.1% (+4.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-0.66), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.09% (CS: 37) | Neutral |
| RSI_14 | 51.0 | Neutral |
| MACD Histogram | -0.66 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.015x | Above |
| vs SMA200 | 1.089x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.21
- **Stop Loss:** $117.55 (4.6% risk)
- **Target:** $128.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 243
- **Position Value:** $29,940.03
- **Portfolio %:** 29.94%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*